Stocks · Healthcare · Biotechnology
Aktis Oncology, Inc. AKTS
$18.52 +0.00% Close, Oct 2, 2026 · NASDAQ · Market cap $989.1M
Low risk
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The stock is 43% below its highest close of the past year.
- The company holds net cash of $71.3M (cash above total debt).
- The diluted share count rose 5.3% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 47%
- Gross marginTop 25%
- Operating marginBottom 13%
- Accruals (lower is better)Bottom 17%
How cheap the shares are relative to earnings, cash flow and their own history.
- Free-cash-flow yieldBottom 40%
- EBITDA / enterprise valueBottom 42%
- Sales / enterprise valueBottom 8%
Strength and persistence of the price trend, including versus the S&P 500.
- 6-month returnTop 50%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 34%
- Upside to consensus price targetTop 37%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 43%
- Maximum drawdown, 3 yearsTop 16%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Gross margin | 84.8% | — | Top 25% | |
| Operating margin | -866.6% | — | Bottom 13% | |
| Net margin | -727.0% | — | — | |
| Free-cash-flow margin | -840.6% | — | — | |
| Return on invested capital | -16.5% | — | Top 47% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 0.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 53.7%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -34.40%
- Shareholder yield
- -34.40%
- Share count change, 1 year
- +5.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +2.1%
- Positive 20 days after report
- 2 of 3
Analysts
- Consensus price target
- $37.40
- Target vs current price
- +101.9%
- Analysts with a rating
- 9
- Share rating Buy or Strong Buy
- 67%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | -2.2% | -0.9% | +4.2% | -0.2% | — |
| May 11, 2026 | -22.6% | -1.8% | +5.1% | +2.0% | +21.8% |
| Mar 30, 2026 | +15.8% | +8.9% | +7.8% | +32.3% | +88.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.44 | -$0.43 | -2.2% | $3.4M |
| May 11, 2026 | -$0.38 | -$0.31 | -22.6% | $3.2M |
| Mar 30, 2026 | -$18.19 | -$21.59 | +15.8% | $1.9M |
| Dec 3, 2025 | -$1.39 | -$0.11 | -1163.6% | $4.6M |
| Nov 14, 2024 | -$0.04 | -$0.10 | +60.0% | — |
| May 13, 2024 | -$0.14 | -$0.12 | -16.7% | — |
| Feb 13, 2024 | -$0.19 | -$0.18 | -5.6% | — |
| Nov 13, 2023 | -$0.26 | -$0.18 | -44.4% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 91.23× | — | — | Bottom 8% |
| Free-cash-flow yield | -8.55% | — | — | Bottom 40% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- 50-day average slope (20 days)
- -8.9%
- Distance from 50-day average
- -20.8%
- RSI (14)
- 26.3
- Relative volume
- 0.69×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 52.1%
- Current drawdown from 1-year high
- -42.5%
- Maximum drawdown, 3 years
- -42.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jun 30, 2026 | Oct 1, 2026 | -42.5% | 65 days | Not yet recovered |
| Jan 22, 2026 | Mar 27, 2026 | -32.2% | 45 days | 55 days (Jun 16, 2026) |
| Jan 9, 2026 | Jan 20, 2026 | -16.2% | 6 days | 2 days (Jan 22, 2026) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $989.1M
- Revenue (TTM)
- $10.1M
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1.5M | $6.5M |
| Gross profit | $0 | $0 | $1.5M | $6.5M |
| Operating income | -$19.8M | -$34.8M | -$52.0M | -$74.7M |
| Net income | -$17.9M | -$28.6M | -$44.0M | -$63.7M |
| EPS (diluted) | -$0.51 | -$0.82 | -$1.26 | -$1.19 |
| Q4 2024 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|
| Revenue | $933,000 | $1.6M | $1.9M | $3.2M | $3.4M |
| Net income | -$12.1M | -$15.5M | -$15.1M | -$18.3M | -$24.1M |
| EPS (diluted) | -$0.23 | — | -$0.28 | -$0.33 | -$0.44 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Operating cash flow | -$18.1M | -$30.0M | $14.8M | -$64.1M |
| Capital expenditure | -$2.3M | -$3.8M | -$2.9M | -$9.6M |
| Free cash flow | -$20.4M | -$33.8M | $11.9M | -$73.7M |
| Dividends paid | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $0 | $0 | $336,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $517.3M
- Total assets
- $557.6M
- Total liabilities
- $72.8M
- Total debt
- $11.2M
- Net debt
- -$71.3M
- Shareholders’ equity
- $484.8M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 3,252,475
- Days to cover
- 11.53
- Change vs previous report
- +2.4%
FINRA short interest, settlement date Sep 15, 2026.